News and Events

Successful FDA End-of-Phase 2 for Hatchtech Head Lice Product DeOVO™

5/09/2012 | Press Releases

Specialty pharmaceutical company Hatchtech Pty Ltd announced today that it had successfully completed end-of-phase 2 (EOP2) consultations with the US Food & Drug Administration (FDA) for its lead product DeOvo™, a single application topical treatment for head lice.

Download PDF